荣昌生物：泰它西普治疗原发性干燥综合征中国III期临床研究达到主要终点

Core Viewpoint - Rongchang Biologics announced that its dual-target fusion protein drug, Taisip (brand name: Tai'ai), has achieved the primary endpoint of its Phase III clinical trial for the treatment of primary Sjögren's syndrome (pSS) in China [1] Group 1 - The drug Taisip is the world's first BLyS/APRIL dual-target fusion protein [1] - The company plans to submit a marketing application to the National Medical Products Administration (NMPA) as soon as possible [1] - Specific data from the clinical trial will be presented at major international academic conferences at an appropriate time [1]